NCT02448251 - Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

AC0010MA

Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.

Trial Locations (8)

CEPCM - Hopital Timone, Marseille

START-Madrid-FJD, Madrid

START-Madrid-CIOCC, Madrid

Emory University School of Medicine, Atlanta

MD Anderson Cancer Center, Houston

City of Hope Comprehensive Cancer Center, Duarte

Stanford University, Palo Alto

Hospital Universitari Vall d'Hebron, Barcelona